Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?
Malek
Sami N
SN
Gore
Steven D
SD
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D004264:DNA Topoisomerases, Type I; D004273:DNA, Neoplasm / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000201:enzymology; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D012074:Remission Induction; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D019772:Topotecan / Q000008:administration & dosage; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D005047:Etoposide; D019772:Topotecan; D004264:DNA Topoisomerases, Type I